Raymond James hires three biotech banking and capital markets veterans
ST. PETERSBURG, Fla. – Raymond James is significantly expanding its Investment Banking and Equity Capital Markets capabilities in biotechnology with the hiring of three senior professionals. These new additions reinforce the firm’s commitment to grow its presence in biotechnology across the entire Capital Markets & Advisory platform.
Richard Hsieh joins the firm’s Healthcare Investment Banking group as a managing director focused on biotechnology. With more than 20 years of experience in investment banking, Hsieh brings deep expertise in M&A, IPOs, PIPEs, equity follow-ons and convertible financings. He joins Raymond James from RBC Capital Markets where he led strategic advisory, M&A and capital markets transactions for biotech companies.
Susan Kirtland has also joined the firm’s Healthcare Investment Banking group as a managing director focused on biotechnology. Kirtland brings over 20 years of experience advising biopharma and life sciences companies on strategic and capital markets transactions. Prior to joining the firm, she served as a managing director at Stifel, focused on capital markets and strategic advisory for her biotech clients.
Medha Chadha joins Raymond James to lead the firm’s Equity Capital Markets efforts across healthcare, with a focus on biotechnology. Chadha brings more than 20 years of capital markets experience raising over $100 billion in equity capital for companies via IPOs, follow-on offerings, PIPES/RDs and private placements. Chadha joins Raymond James after four years as head of healthcare capital markets advisory at Lazard, where she advised corporates on capital formation and shareholder engagement.
“We are very excited to welcome Rich, Susan and Medha to the firm. They are very talented senior professionals who will bolster our strategic advisory capabilities in the biotechnology industry,” said Doug Brown, head of Healthcare Investment Banking.
Together, these three will work alongside managing director Brian Gleason, who has played a central role in the Raymond James biotech investment banking practice for the past three years after joining the firm from Citibank where he spent 18 years advising and executing biotechnology capital markets transactions, and Ed Newman, who has ably served on Raymond James’ Equity Capital Markets desk for the last 10 years.
The addition of Richard, Susan and Medha complement the firm’s recent investment in biotech equity research with the hiring of senior analysts Marty Auster and Chris Raymond this past summer. These experienced hires bring the necessary leadership and strategic thinking to drive the firm’s success in biotechnology banking, capital markets and research.
“Raymond James is deeply committed to supporting biotech companies as they navigate complex markets, scale transformative technologies and unlock new opportunities for strategic partnerships and capital formation,” said Jim Bunn, president, Capital Markets & Advisory. “The continued expansion of our biotech practice reflects the strategic importance of the sector across our Capital Markets platform. Rich, Susan and Medha bring exceptional credentials and a track record of client-focused execution, enhancing our ability to deliver specialized, high-impact advice to biotech innovators.”
About Raymond James Financial, Inc.
Raymond James Financial, Inc. (NYSE: RJF) is a leading diversified financial services company providing private client group, capital markets, asset management, banking and other services to individuals, corporations and municipalities. Total client assets are $1.69 trillion. Public since 1983, the firm is listed on the New York Stock Exchange under the symbol RJF. Additional information is available at www.raymondjames.com. Raymond James & Associates, Inc., member New York Stock Exchange/SIPC.